NAI Hunneman Brokers Lease for DrugDev, a Fast-Growing Clinical Trials Technology Company, at 25 Thomson Place in Boston Waterfront
Gallagher & Davis represent DrugDev in relocation to 16,437 SF in the Innovation District
NAI Hunneman recently completed a 16,437 SF lease transaction with DrugDev at 25 Thomson Place in Boston’s Innovation District. The fast-growing global clinical trials technology and management solutions company, which works with nearly all of the top pharmaceutical companies, is relocating its Boston area operations (focused primarily on SaaS solution development and customer project management) from Newton, MA. DrugDev maintains its corporate headquarters in King of Prussia, PA, with additional offices in Boston and London.
NAI Hunneman Executive Vice President Evan Gallagher and Associate Matt Davis represented DrugDev in the transaction while the landlord was represented by Thomas O’Regan from JLL.
“DrugDev is a rapidly growing and exciting client. They were very thoughtful in their evaluation of a new location that will attract and retain the best workforce to support their evolving business,” said Gallagher. “NAI Hunneman was there to support and guide them through that process, evaluating multiple markets and helping them understand what each market could offer their employees. We are very excited about their decision and the positive impact it will have on the culture and future success of the company.”
”DrugDev technology continues to transform the way pharmaceutical companies run clinical trials – making them faster and more efficient, so they can bring more treatments to patients worldwide,” said Brian Fisher, Chief Operating Officer of DrugDev’s Boston operations. “As demand for our solutions continues to grow, we need to remain committed to attaining and retaining the best possible talent available. Boston’s Innovation District on the waterfront is an ideal intersection of technology, life sciences and business expertise. Coupled with our collaborative corporate culture, the new Boston office will feature a shared open environment that brings out the best in our team to benefit customers – and ultimately patients – worldwide.”
DrugDev’s unified clinical suite enables sponsors, CROs and sites to do more trials through industry-wide collaboration, standardization and a beautiful technology experience. Featuring solutions for global site payments, site identification and activation, workflow optimization, learning management, and site and patient engagement, DrugDev helps companies transform the quality and efficiency of clinical trials from startup through closeout. The company also powers the revolutionary TransCelerate Investigator Registry and Investigator Databank collaborations with the universal identifier known as the DrugDev Golden Number. www.drugdev.com
Headquartered in Boston, NAI Hunneman is a leading provider of commercial real estate services to corporations, institutions and the private market. NAI Hunneman is a member NAI Global, the premier network of independent commercial real estate firms and one of the largest commercial real estate service providers worldwide. NAI Global manages a network of 6,700 professionals and 375 offices throughout the world. NAI professionals work together with its global management team to help clients strategically optimize their real estate assets. To learn more about NAI Hunneman and the NAI Global Network please visit www.naihunneman.com.